🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
43.11
+0.12 (0.28%)
At close: Nov 18, 2026, 4:00 PM EST
43.01
-0.10 (-0.23%)
After-hours: Nov 18, 2026, 5:02 PM EST

Company Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.

The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy.

In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials.

The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; Novartis Pharma AG; Madrigal Pharmaceuticals, Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals logo
CountryUnited States
Founded2003
IPO DateJun 16, 1993
IndustryBiotechnology
SectorHealthcare
Employees1,062
CEOChristopher Anzalone

Contact Details

Address:
177 East Colorado Boulevard, Suite 700
Pasadena, California 91105
United States
Phone626 304 3400
Websitearrowheadpharma.com

Stock Details

Ticker SymbolARWR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearOctober - September
Reporting CurrencyUSD
CIK Code0000879407
CUSIP Number04280A100
ISIN NumberUS04280A1007
Employer ID46-0408024
SIC Code2834

Key Executives

NamePosition
Dr. Christopher R. Anzalone Ph.D.Chairman, Chief Executive Officer and President
Daniel J. ApelChief Financial Officer
Patrick O'Brien J.D., PharmDChief Operating Officer and Secretary
Dr. James C. Hamilton M.D., MBAChief Medical Officer and Head of Research & Development
Dr. Mark M. Davis Ph.D.Founder and Founder and Director of Insert Therapeutics Inc & Calando
Dr. Tao Pei Ph.D.Chief Scientific Officer
Dr. Vincent Anzalone CFAHead of Investor Relations and Vice President
Howard LovyDirector of Communications
Dr. Bruce D. Given M.D.Chief Medical Scientist
Dr. Mark SeefeldHead of Toxicology and Vice President

Latest SEC Filings

DateTypeTitle
Nov 12, 202610-KAnnual Report
Nov 12, 20268-KCurrent Report
Nov 5, 2026SCHEDULE 13G/AFiling
Nov 4, 20268-KCurrent Report
Aug 18, 2026144Filing
Aug 18, 2026144Filing
Aug 14, 2026SCHEDULE 13G/AFiling
Aug 4, 20268-KCurrent Report
Aug 4, 202610-QQuarterly Report
Jul 31, 2026SCHEDULE 13G/AFiling
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides